Dr Agarwals Eye Hospital Ltd.
| BSE: 526783 | Sector: Health care |
| NSE: N.A. | ISIN Code: INE934C01018 |
| BSE 00:00 | 07 May | 385.00 |
8.15 (2.16%) |
OPEN
365.05 |
HIGH
394.95 |
LOW
365.05 |
| NSE 05:30 | 01 Jan | Dr Agarwals Eye Hospital Ltd |
| OPEN | 365.05 |
| PREVIOUS CLOSE | 376.85 |
| VOLUME | 3088 |
| 52-Week high | 416.20 |
| 52-Week low | 190.00 |
| P/E | |
| Mkt Cap.(Rs cr) | 181 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
Dr Agarwals Eye Hospital Ltd. (DRAGARWALSEYE) - News Sector
-
Amid supply crunch, private hospitals eyeing import of Covid-19 vaccines
10.39 pm | 7 May 2021 | Business Standard
Two major hospital groups, Apollo Hospitals and Fortis Healthcare, said they are open to exploring opportunities to import
-
Amid supply crunch, private hospitals eyeing import of Covid-19 vaccines
10.39 pm | 7 May 2021 | Business Standard
Two major hospital groups, Apollo Hospitals and Fortis Healthcare, said they are open to exploring opportunities to import
-
India's pharma market rebounds in April, clocks 51.5% sales growth
10.06 pm | 7 May 2021 | Business Standard
Low base of April 2020, pick-up in demand for Covid-19 drugs major contributors to growth
-
India's pharma market rebounds in April, clocks 51.5% sales growth
10.06 pm | 7 May 2021 | Business Standard
Low base of April 2020, pick-up in demand for Covid-19 drugs major contributors to growth
-
India's pharma market rebounds in April, clocks 51.5% sales growth
10.06 pm | 7 May 2021 | Business Standard
Low base of April 2020, pick-up in demand for Covid-19 drugs major contributors to growth
-
Anupam Rasayan rallies 13% in 2 days after Plutus Wealth buys stake
12.32 pm | 6 May 2021 | Business Standard
On May 5, Plutus Wealth Management purchased 1 million shares, representing 1 per cent stake of Anupam Rasayan India, for Rs 64.75 crore
-
Lupin soars 8%, hits over three-year high on heavy volumes
11.33 am | 5 May 2021 | Business Standard
The stock surpassed its previous high of Rs 1,121.85 touched on September 2020 and was trading at the highest level since July 2017
-
Alembic Pharma falls 6% post March quarter results
10.04 am | 5 May 2021 | Business Standard
Alembic Pharma Q4FY21 operational performance was marginally below estimates, largely due to lower traction in US and Domestic Formulation (DF) sales
-
Hikal hits new high on signing 10-year deal with global pharma Co
9.36 am | 5 May 2021 | Business Standard
This contract entails the development and supply of a portfolio of niche APIs (Active Pharmaceutical Ingredient) over a period of 10 years
-
Nifty close below 14,416 would be bearish for short-term: Vinay Rajani
8.28 am | 5 May 2021 | Business Standard
Below 14,416, Nifty could slide towards next support of 14,150
-
Pricing pressure in US market to impact margins of pharma companies
11.48 pm | 4 May 2021 | Business Standard
Lack of new launches due to inspection delays, intensifying competition key headwinds
-
Alembic Pharma Q4 net up 12% to Rs 251 cr on strong API, global businesses
8.24 pm | 4 May 2021 | Business Standard
Net sales rise 6% to Rs 1,280 cr; API business expands by as much as 38%
-
Consolidation continues on D St; Sensex falls 465 pts; Nifty PSU Bank up 3%
4.20 pm | 4 May 2021 | Business Standard
Nearly 35 of the 50 constituents on the index ended the day in the red including Tata Consumer Products (down 4.3 per cent), Cipla, Reliance Industrie...
-
All you need to know about Commodity Channel Index in trading
8.34 am | 4 May 2021 | Business Standard
The basic philosophy of CCI is based on the assumption that commodities, stocks and bonds trade in a cycle with a peak and a trough arrived at on a pe...
-
This smallcap pharma stock has zoomed 101% in a month
12.52 pm | 3 May 2021 | Business Standard
On April 28, Morepen Group sealed $100 million (Rs 750 crore approx.) investment from Corinth Group of Switzerland
-
Laurus Labs shares advance 5% on strong growth outlook
11.50 am | 3 May 2021 | Business Standard
Laurus is well poised to follow the success story of some leading CDMO players backed by strong chemistry and integrated model
-
Natco Pharma gains 4% on emergency use approval for Covid-19 medicine
11.03 am | 3 May 2021 | Business Standard
The company has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (...
-
Top trading ideas by Bharat Gala of Ventura Sec: Buy Nocil, Divi's Labs
8.58 am | 3 May 2021 | Business Standard
Recently, the stock of Divi's Labs has given a weekly range breakout, making a new high of 4133, supported by volumes
-
Amid weak showing by biosimilars and generics, downgrade pressure on Biocon
11.27 pm | 2 May 2021 | Business Standard
Analysts expect ramp-up in biosimilars to be gradual
-
Govt should have built safety stock of essential drugs: Kiran Mazumdar-Shaw
10.28 pm | 30 Apr 2021 | Business Standard
The Biocon founder and Executive Chairperson points out that drugs like Remdesivir should be allowed at home as an emergency step
Quick Links for Dr Agarwals Eye Hospital:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
